MELPHALAN HYDROCHLORIDE | DELCATH SYSTEMS INC | ||
EQ 50MG BASE/VIAL | |||
No | Yes | ||
2034-Sep-17 | Expired | ||
None | 2026-Aug-14 | ||
None | No | ||
HEPZATO is an alkylating drug indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. |
0 | 0 | 0 |
Total Other Developers | None |
---|
Drugs with Suitability | No |
---|
EQ 50MG BASE/VIAL | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
No | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com